Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16765207 | 1.00 | HPGD (0.39) | HPGDALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL30471621 | 1.00 | HPGD (0.39) | HPGDALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL16786562 | 0.86 | HPGD (0.42) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL16789933 | 0.84 | ALDH1A1 (0.39) | HPGDALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL9962386 | 0.82 | HPGD (0.45) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL30242026 | 0.82 | HPGD (0.45) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL28169096 | 0.82 | HPGD (0.45) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL9962406 | 0.81 | HPGD (0.44) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL9933726 | 0.80 | HPGD (0.43) | HPGDALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL22240465 | 0.80 | HPGD (0.41) | HPGDALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417389-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-12-19 | — | — | US | disclosed |
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11174243-B2 | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210032218-A1 | SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-02-04 | — | — | US | disclosed |
| US-20210017155-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3753934-A1 | PYRIMIDINYL DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3385263-B1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10618887-B2 | Pyrimidinyl tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190047986-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-02-14 | — | — | US | disclosed |
| EP-3385263-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2858499-B1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944622-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160304494-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-10-20 | — | — | US | disclosed |
| US-9394277-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150158843-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017155-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | HPGD 3714/4885ALDH1A1 3713/4885MEN1 3197/4885 |
| US-20240417389-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | HPGD 3714/4885ALDH1A1 3713/4885MEN1 3197/4885 |
| US-11174243-B2 | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors | ABL1, SRC, BTK | HPGD 1531/4885ALDH1A1 3327/4885MEN1 2896/4885 |
| US-20210032218-A1 | SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, SRC, BTK | HPGD 1531/4885ALDH1A1 3327/4885MEN1 2896/4885 |
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | HPGD 3961/4885ALDH1A1 3781/4885MEN1 3090/4885 |
| US-20150158843-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | HPGD 3714/4885ALDH1A1 3713/4885MEN1 3197/4885 |
| US-20190047986-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | HPGD 3714/4885ALDH1A1 3713/4885MEN1 3197/4885 |
| US-20160304494-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | HPGD 3714/4885ALDH1A1 3713/4885MEN1 3197/4885 |
| US-10618887-B2 | Pyrimidinyl tyrosine kinase inhibitors | ABL1, BTK, ABL2 | HPGD 3714/4885ALDH1A1 3713/4885MEN1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.